One year has passed since we said goodbye to Dr. Ciro de Quadros, Sabin Vaccine Institute’s former Executive Vice President and Director of our Vaccine Advocacy and Education program. Best known for his tireless work to...
DVI is delighted to announce the appointment of Professor Annelies Wilder-Smith as Senior Advisor to the DVI, effective immediately.
Thursday, May 29, 2014
Dr. Ciro de Quadros, a public health hero and the Sabin Vaccine Institute’s Executive Vice President and Director of Vaccine Advocacy and Education, passed away peacefully yesterday at his home in Washington, DC, surrounded by his family. The following are statements from Sabin’s executive leadership reflecting on the profound difference that Ciro made during his lifetime.
Six dengue vaccine candidates are in various stages of clinical development but developing countries will not receive the benefits if planning does not start now.
The Dengue Vaccine Initiative (DVI) announced today that it has received a 1 million Euro award from the German Federal Ministry of Education and Research (BMBF), the first time it has received such a grant from Germany. The funds will be used to support the development of new dengue vaccines in collaboration with the Instituto Butantan, a biomedical research center in São Paulo, Brazil, and Vabiotech, a vaccine manufacturer in Hanoi, Vietnam.
Held October 24-25 in Bangkok, Thailand, this meeting gathered together representatives from the Ministries of Health (MOH) and National Regulatory Authorities (NRA) of early adopter countries of a dengue vaccine, namely Thailand, Brazil, Colombia, Indonesia, Malaysia, Mexico and the Philippines. There were two parallel sessions: an open session with representatives from MOH, DVI, manufacturers and invited guests, and a closed session between NRAs.
The Consolidated Points for Consideration provides a framework for helping countries interested in being among the first to introduce a dengue vaccine to consider the elements needed for vaccine introduction, and to plan and start preparation in a timely manner.
On May 7th, Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that they have entered into a definitive agreement for Takeda to acquire Inviragen, whose DENVax dengue vaccine candidate is currently being evaluated in dengue endemic areas.